Bigstocka
Posted - 20 hours ago
$NRSN look into LASE looks good
History101
Posted - 20 hours ago
$NRSN adding
History101
Posted - 20 hours ago
$NRSN 3,198 watching 4/19/2024
black_ambition
Posted - 21 hours ago
@Powderedtoastman1 Why do you think $NRSN currently has a market cap only 1/5th od $AMLX, even after their ALS failure?
black_ambition
Posted - 22 hours ago
The clinical results seem very impressive, yet the stock is performing very poorly. I wonder why it does not appear that a larger biopharma company is interested in partnering with $NRSN. Any thoughts?
Fighting_ALS
Posted - 22 hours ago
$NRSN Best outcome in a Phase 2 study: "What we can learn from this is that, particularly in the people who started the drug earlier in their illness, that’s where we saw the largest difference." Merit E. Cudkowicz, MD https://alsnewstoday.com/aan-2024/aan-2024-primec-lowered-nfl-nerve-damage-biomarker-als-trial/
black_ambition
Posted - 23 hours ago
@Dorrrrr Yes it has. I suggest that you sign up at the $NRSN website in order to get on their email list for press releases and SEC filings. That will help keep you up to date about what is happening.
Simon555
Posted - 23 hours ago
black_ambition
Posted - 1 day ago
@Dorrrrr I don't believe Lonza is a partner who might ever buy $NRSN. Based on the recent price action, it seems like the market agrees with me. Biogen was putting funds up as a part of the partnership. It's not clear to me what the level of investment/commitment Lonza has as a result of what was announced.
black_ambition
Posted - 1 day ago
@Dorrrrr You're very welcome. I have followed, researched, and owned a considerable amount of this stock for a long time. I am extremely frustrated by what I believe is a large disconnect between $NRSN fundamentals/prospects and its share price.
boilerrm04
Posted - 1 day ago
@black_ambition $amlx has nothing and is still trading 7x $NRSN
boilerrm04
Posted - 1 day ago
$NRSN what was so late breaking about announcing already published results? Doesnt make any sense.
black_ambition
Posted - 1 day ago
@Dorrrrr FDA approval based on the Phase 2b results would cause the stock to SKYROCKET. Because of 1) the backlash associated with the Phase 2 approval for Amylyx, which subsequently was pulled, plus 2) the fact that none of the $NRSN Phase 2b trial was conducted in the U.S., I believe that U.S. FDA approval is unlikely without a full Phase 3 trial.
Dorrrrr
Posted - 1 day ago
$NRSN Is there a date range for publication. Does the company receive fda phase 3
My_Lai_1968
Posted - 1 day ago
$NRSN I told you that this would plunge.
Dorrrrr
Posted - 1 day ago
$NRSN It is very strange that despite data there are declines
what do you say?
boilerrm04
Posted - 1 day ago
$NRSN a little odd that the nfl biomarker wasn’t disclosed just “trending positive” perhaps ongoing treatment keeps increasing the response rate, curious to ex some combination treatment results which should help accelerate FDA approval and partnership/buyout suitors.
Mikeqb20
Posted - 1 day ago
$NRSN adding here MOFO’s
Simon555
Posted - 2 days ago
$NRSN No news as expected, no news till the 3rd phase trial data in few months combining with bull market. Selloff is coming
premarketmaker
Posted - 2 days ago
$NRSN current view and today's lines
premarketmaker
Posted - 2 days ago
$NRSN
premarketmaker
Posted - 2 days ago
$NRSN this could be our wild card today 10M float with positive data Phase 2b
DonCorleone77
Posted - 2 days ago
$NRSN NeuroSense reports Phase 2b neurology results of PrimeC NeuroSense announced the presentation of data from the company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. The study also demonstrated a positive trend toward impact on Neurofilament levels. The study showed that PrimeC, a formulation of specific doses of ciprofloxacin and celecoxib, met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% in the per-protocol population. Further, the data showed supporting trends in biomarkers, specifically Neurofilament.
Powderedtoastman1
Posted - 2 days ago
$NRSN news comes out that looks promising. Markets response let's sell it.
OpenOutcrier
Posted - 2 days ago
$NRSN (+8.1% pre) Neurosense Therapeutics (NRSN) Reports Positive Data Validating Phase 2b Topline Readout - SI https://ooc.bz/l/30722
Tommy_Two_Toes
Posted - 2 days ago
$NRSN bam
Stock_Titan
Posted - 2 days ago
$NRSN NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
https://www.stocktitan.net/news/NRSN/neuro-sense-presents-positive-data-validating-phase-2b-topline-srps4cxd6qlw.html
Mikeqb20
Posted - 2 days ago
$NRSN SPOT ON @LRaye PERFECT POST LOAD UP ON $NRSN
LRaye
Posted - 3 days ago
$NRSN this is one of those tickers where people are going to say “where did that come from? “. Boy I missed that one.”